ROS1 and adenocarcinoma: Another female patient in her 40s diagnosed with adenocarcinoma mixed with neuroendocrine carcinoma of the uterus revealed GOPC-ROS1 fusion from a prior tissue NGS test and had received crizotinib (Figure 4B).